Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Inhaled aztreonam.

O'Sullivan BP, Yasothan U, Kirkpatrick P.

Nat Rev Drug Discov. 2010 May;9(5):357-8. doi: 10.1038/nrd3170.

PMID:
20431562
2.

Aztreonam lysine for inhalation: new formulation of an old antibiotic.

Zeitler K, Salvas B, Stevens V, Brown J.

Am J Health Syst Pharm. 2012 Jan 15;69(2):107-15. doi: 10.2146/ajhp100624. Review.

PMID:
22215356
3.
4.

Aztreonam lysine for inhalation solution: in cystic fibrosis.

Plosker GL.

Drugs. 2010 Oct 1;70(14):1843-55. doi: 10.2165/10484070-000000000-00000. Review.

PMID:
20836577
5.

Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis.

Parkins MD, Elborn JS.

Expert Rev Respir Med. 2010 Aug;4(4):435-44. doi: 10.1586/ers.10.48. Review.

PMID:
20658904
6.

Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.

Elborn JS, Henig NR.

Expert Opin Pharmacother. 2010 Jun;11(8):1373-85. doi: 10.1517/14656566.2010.482102. Review.

PMID:
20426707
7.

Inhaled aztreonam lysine: an evidence-based review.

Hutchinson D, Barclay M, Prescott WA, Brown J.

Expert Opin Pharmacother. 2013 Oct;14(15):2115-24. doi: 10.1517/14656566.2013.831070. Epub 2013 Aug 31. Review.

PMID:
23992352
8.

Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.

Máiz L, Girón RM, Olveira C, Quintana E, Lamas A, Pastor D, Cantón R, Mensa J.

Expert Opin Pharmacother. 2013 Jun;14(9):1135-49. doi: 10.1517/14656566.2013.790366. Epub 2013 Apr 16. Review.

PMID:
23586963
9.

Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes.

Pesaturo KA, Horton ER, Belliveau P.

Ann Pharmacother. 2012 Jul-Aug;46(7-8):1076-85. doi: 10.1345/aph.1Q653. Epub 2012 Jul 3. Review.

PMID:
22764322
10.

Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.

Assael BM.

Expert Rev Anti Infect Ther. 2011 Nov;9(11):967-73. doi: 10.1586/eri.11.131. Review.

PMID:
22029514
11.

Aerosolized antibiotics in cystic fibrosis: an update.

Fiel SB.

Expert Rev Respir Med. 2014 Jun;8(3):305-14. doi: 10.1586/17476348.2014.896205. Review.

PMID:
24838090
12.

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.

Langton Hewer SC, Smyth AR.

Cochrane Database Syst Rev. 2014 Nov 10;(11):CD004197. doi: 10.1002/14651858.CD004197.pub4. Review.

PMID:
25383937
13.

Aztreonam for inhalation solution (Cayston) for cystic fibrosis.

[No authors listed]

Med Lett Drugs Ther. 2010 Aug 9;52(1344):63-4. Review. No abstract available.

PMID:
20697341
14.

Update in cystic fibrosis 2009.

Mogayzel PJ Jr, Flume PA.

Am J Respir Crit Care Med. 2010 Mar 15;181(6):539-44. doi: 10.1164/rccm.200912-1943UP. Review. No abstract available.

PMID:
20208039
15.

[How should chronic Pseudomonas aeruginosa bronchial infection be treated in the course of cystic fibrosis?].

Hubert D, Desmazes-Dufeu N, Dusser D.

Rev Mal Respir. 2003 Apr;20(2 Pt 2):S129-35. Review. French. No abstract available.

PMID:
12910145
16.

Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.

Høiby N.

BMC Med. 2011 Apr 4;9:32. doi: 10.1186/1741-7015-9-32. Review.

17.

Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis.

Stockmann C, Hillyard B, Ampofo K, Spigarelli MG, Sherwin CM.

Expert Rev Respir Med. 2015 Feb;9(1):13-22. doi: 10.1586/17476348.2015.986469. Epub 2014 Nov 24. Review.

PMID:
25417708
18.

New developments in inhaled antibiotics for the treatment of Pseudomonas aeruginosa.

Hofmann T.

Curr Pharm Des. 2012;18(5):683-95. Review.

PMID:
22229573
19.

[TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].

Pierart F.

Rev Med Liege. 2013 Sep;68(9):486-8. Review. French.

PMID:
24180205
20.

Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.

Vazquez-Espinosa E, Marcos C, Alonso T, Giron RM, Gomez-Punter RM, Garcia-Castillo E, Zamora E, Cisneros C, Garcia J, Valenzuela C, Ancochea J.

Expert Rev Anti Infect Ther. 2016;14(1):9-17. doi: 10.1586/14787210.2016.1118344. Epub 2015 Dec 4. Review.

PMID:
26559549

Supplemental Content

Support Center